2023–2024 Drug Updates in Hematologic Malignancies

At the highly anticipated session at JADPRO Live 2024, Oxana Megherea, PharmD, BCOP, covered several newly approved therapies for patients with multiple myeloma, leukemia, lymphoma, and other hematologic malignancies, including their mechanisms of action and strategies for managing adverse events.

Publication Details

Journal
Journal of the Advanced Practitioner in Oncology
Published
2025-03-25
DOI
https://doi.org/10.6004/jadpro.2025.16.2.9
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

2023–2024 Drug Updates in Hematologic Malignancies

Journal of the Advanced Practitioner in Oncology
Chronic Lymphocytic Leukemia Research
article

2023–2024 Drug Updates in Hematologic Malignancies

article en

Abstract

At the highly anticipated session at JADPRO Live 2024, Oxana Megherea, PharmD, BCOP, covered several newly approved therapies for patients with multiple myeloma, leukemia, lymphoma, and other hematologic malignancies, including their mechanisms of action and strategies for managing adverse events.

Journal of the Advanced Practitioner in OncologyVol. 16(2)
Openalex Percentile: Top 91%
Chronic Lymphocytic Leukemia Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

2023–2024 Drug Updates in Hematologic Malignancies · Journal of the Advanced Practitioner in Oncology (2025) | TGRS Research Map | TGRS